Table of Contents 2
List of Tables 4
List of Figures 5
Report Guidance 6
GlobalData Clinical Trials Report Coverage 7
Clinical Trials by Region 8
Clinical Trials and Average Enrollment by Country 9
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
Top Five Countries Contributing to Clinical Trials in Europe 12
Top Countries Contributing to Clinical Trials in North America 13
Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
Top Five Countries Contributing to Clinical Trials in Central and South America 15
Clinical Trials by G7 Countries: Proportion of Rel Cell Carcinoma to Oncology Clinical Trials 16
Clinical Trials by Phase in G7 Countries 17
Clinical Trials in G7 Countries by Trial Status 18
Clinical Trials by E7 Countries: Proportion of Rel Cell Carcinoma to Oncology Clinical Trials 19
Clinical Trials by Phase in E7 Countries 20
Clinical Trials in E7 Countries by Trial Status 21
Clinical Trials by Phase 22
In Progress Trials by Phase 23
Clinical Trials by Trial Status 24
Clinical Trials by End Point Status 25
Subjects Recruited Over a Period of Time 26
Clinical Trials by Sponsor Type 27
Prominent Sponsors 28
Top Companies Participating in Rel Cell Carcinoma Therapeutics Clinical Trials 29
Prominent Drugs 30
Latest Clinical Trials News on Rel Cell Carcinoma 31
Jun 20, 2018: SillaJen enrols first patient in REN026 trial 31
Jun 13, 2018: TRACON Announces Presentation Of Preclinical Data From Studies Of TRC105 In Combition With A PD-1 Antibody In Murine Models Of Colorectal Cancer 31
Jun 12, 2018: Surface Oncology Announces Initiation of Phase I Clinical Trial of SRF373 / NZV930 31
Jun 11, 2018: Arcus Biosciences Announces FDA Clearance of INDs for AB928 and AB122 and Initiation of Phase 1/1b Program to Evaluate AB928 Combitions 32
Jun 03, 2018: Merck’s KEYTRUDA (pembrolizumab) Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy in Patients with Advanced Clear Cell Rel Cell Carcinoma (RCC) in Phase 2 KEYNOTE-427 Study 32
Jun 03, 2018: Eisai and Merck Announce Data at 2018 ASCO Annual Meeting from Investigatiol Studies of LENVIMA (lenvatinib) and KEYTRUDA (pembrolizumab) Combition Therapy in Four Different Tumor Types 33
Jun 03, 2018: Phase III Trial Finds Many People With Advanced Kidney Cancer Do Not Need Surgery 35
Jun 01, 2018: Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Rel Cell Carcinoma in CheckMate -214 Study 35
May 17, 2018: Eisai to Present Data on Oncology Pipeline and Products at 54th ASCO Annual Meeting 36
May 16, 2018: New Data from Merck’s Leading Immuno-Oncology Clinical Development Program in Over 25 Tumor Types to Be Presented at 2018 ASCO Annual Meeting 37
May 08, 2018: X4 Pharmaceuticals to Present Clinical Data from Pilot Study of Combition of X4P-001-IO and Opdivo (nivolumab) 38
May 04, 2018: CStone announces first patient dosed with anti-CTLA-4 antibody CS1002 of a Phase I study in Australia 38
Apr 26, 2018: Cabozantinib to Be Featured in 15 Presentations at ASCO 2018 Annual Meeting 39
Apr 12, 2018: GamaMabs Pharma to Present New Data on Expression of Anti-M?llerian Hormone type II Receptor in Non-gynecological Cancers and on First ADC Candidate Targeting AMHRII 40
Apr 10, 2018: Pfizer Provides Update on Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Rel Cell Carcinoma Recurrence After Surgery 40
Clinical Trial Profile Spshots 42
Appendix 979
Abbreviations 979
Definitions 979
Research Methodology 980
Secondary Research 980
About GlobalData 981
Contact Us 981
Disclaimer 981
Source 982